For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...
The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...
Columnist Desiree Lama has accepted her MS diagnosis as part of her identity — but it's not the only thing that defines her, ...
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
PHILADELPHIA.Today on MSN2d
Local Multiple Sclerosis Advocate Honored With State CitationBucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Medpage Today on MSN5d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse OutcomesHigher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback